Confidential and non-confidential drug rebates in Switzerland, 2013–2023: empirical analysis of drug rebates, trends over time and re-evaluations
Noah Rohner, Cascal Herrle, Luca Locher, Kerstin N. Vokinger · 2024
Read Confidential and non-confidential drug rebates in Switzerland, 2013–2023: empirical analysis of drug rebates, trends over time and re-evaluations by Noah Rohner, Cascal Herrle, Luca Locher, Kerstin N. Vokinger (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11551491.txt.
Description
anticipate the presence of a rebate and enter the negotiation with a higher price or because there is a lack of an administrative and technical system to recoup such rebates.3 Confidential rebates may also result in an overpayment in countries that rely on external reference pricing.
Catalog record
| CREATOR | Noah Rohner, Cascal Herrle, Luca Locher, Kerstin N. Vokinger |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |